{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T04:55:49Z","timestamp":1775019349588,"version":"3.50.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"DOI":"10.1007\/s00592-024-02289-y","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T19:01:36Z","timestamp":1715108496000},"page":"1097-1105","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A comprehensive meta-analysis on the association of SGLT2is and GLP-1RAs with vascular diseases, digestive diseases and fractures"],"prefix":"10.1007","volume":"61","author":[{"given":"De-Hua","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Xia","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Yong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6652-8746","authenticated-orcid":false,"given":"Fei","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,7]]},"reference":[{"issue":"10166","key":"2289_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I et al (2019) Sglt2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393(10166):31\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(18)32590-X","journal-title":"Lancet"},{"issue":"11","key":"2289_CR2","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","volume":"7","author":"BL Neuen","year":"2019","unstructured":"Neuen BL, Young T, Heerspink H et al (2019) Sglt2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endo 7(11):845\u2013854. https:\/\/doi.org\/10.1016\/S2213-8587(19)30256-6","journal-title":"Lancet Diabetes Endo"},{"issue":"10","key":"2289_CR3","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee M, Kristensen SL et al (2021) Cardiovascular, mortality, and kidney outcomes with glp-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endo 9(10):653\u2013662. https:\/\/doi.org\/10.1016\/S2213-8587(21)00203-5","journal-title":"Lancet Diabetes Endo"},{"issue":"10","key":"2289_CR4","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen SL, Rorth R, Jhund PS et al (2019) Cardiovascular, mortality, and kidney outcomes with glp-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endo 7(10):776\u2013785. https:\/\/doi.org\/10.1016\/S2213-8587(19)30249-9","journal-title":"Lancet Diabetes Endo"},{"issue":"10365","key":"2289_CR5","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"Writing Committee","year":"2022","unstructured":"Writing Committee, Smart-C Steering Committee (2022) Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400(10365):1788\u20131801. https:\/\/doi.org\/10.1016\/S0140-6736(22)02074-8","journal-title":"Lancet"},{"issue":"7","key":"2289_CR6","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.015323","volume":"9","author":"M Hu","year":"2020","unstructured":"Hu M, Cai X, Yang W, Zhang S, Nie L, Ji L (2020) Effect of hemoglobin a1c reduction or weight reduction on blood pressure in glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter-2 inhibitor treatment in type 2 diabetes mellitus: a meta-analysis. J Am Heart Assoc 9(7):e15323. https:\/\/doi.org\/10.1161\/JAHA.119.015323","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"2289_CR7","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1111\/dom.14451","volume":"23","author":"A Tsapas","year":"2021","unstructured":"Tsapas A, Karagiannis T, Kakotrichi P et al (2021) Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Obes Metab 23(9):2116\u20132124. https:\/\/doi.org\/10.1111\/dom.14451","journal-title":"Diabetes Obes Metab"},{"key":"2289_CR8","doi-asserted-by":"publisher","DOI":"10.1177\/20420188221142450","author":"B Ren","year":"2022","unstructured":"Ren B, Chen M (2022) Effect of sodium-glucose cotransporter-2 inhibitors on patients with essential hypertension and pre-hypertension: a meta-analysis. Ther Adv Endocrinol. https:\/\/doi.org\/10.1177\/20420188221142450","journal-title":"Ther Adv Endocrinol"},{"key":"2289_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12030772","author":"C Kennedy","year":"2023","unstructured":"Kennedy C, Hayes P, Salama S, Hennessy M, Fogacci F (2023) The effect of semaglutide on blood pressure in patients without diabetes: a systematic review and meta-analysis. J Clin Med. https:\/\/doi.org\/10.3390\/jcm12030772","journal-title":"J Clin Med"},{"issue":"1","key":"2289_CR10","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13098-023-01092-z","volume":"15","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Zhou S, Liu L (2023) Efficacy and safety evaluation of sglt2i on blood pressure control in patients with type 2 diabetes and hypertension: a new meta-analysis. Diabetol Metab Syndr 15(1):118. https:\/\/doi.org\/10.1186\/s13098-023-01092-z","journal-title":"Diabetol Metab Syndr"},{"key":"2289_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.724405","author":"DG Yin","year":"2021","unstructured":"Yin DG, Qiu M, Duan XY (2021) Association between sglt2is and cardiovascular and respiratory diseases: a meta-analysis of large trials. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2021.724405","journal-title":"Front Pharmacol"},{"issue":"5","key":"2289_CR12","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1097\/FJC.0000000000001222","volume":"79","author":"HT Zou","year":"2022","unstructured":"Zou HT, Yang GH, Cai YJ, Chen H, Zheng XQ, Hu R (2022) Are high- or low-dose sglt2 inhibitors associated with cardiovascular and respiratory adverse events? A meta-analysis. J Cardiovasc Pharm 79(5):655\u2013662. https:\/\/doi.org\/10.1097\/FJC.0000000000001222","journal-title":"J Cardiovasc Pharm"},{"issue":"5","key":"2289_CR13","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/jcpt.13588","volume":"47","author":"XX Liao","year":"2022","unstructured":"Liao XX, Li WQ, Peng ZK, Yu HB, Tan J (2022) Three new categories of hypoglycaemic agents and various cardiovascular diseases: a meta-analysis. J Clin Pharm Ther 47(5):636\u2013642. https:\/\/doi.org\/10.1111\/jcpt.13588","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"2289_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C et al (2023) Empagliflozin in patients with chronic kidney disease. New Engl J Med 388(2):117\u2013127. https:\/\/doi.org\/10.1056\/NEJMoa2204233","journal-title":"New Engl J Med"},{"issue":"16","key":"2289_CR15","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. New Engl J Med 385(16):1451\u20131461. https:\/\/doi.org\/10.1056\/NEJMoa2107038","journal-title":"New Engl J Med"},{"issue":"12","key":"2289_CR16","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray J, Claggett B et al (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. New Engl J Med 387(12):1089\u20131098. https:\/\/doi.org\/10.1056\/NEJMoa2206286","journal-title":"New Engl J Med"},{"issue":"2","key":"2289_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG et al (2021) Sotagliflozin in patients with diabetes and recent worsening heart failure. New Engl J Med 384(2):117\u2013128. https:\/\/doi.org\/10.1056\/NEJMoa2030183","journal-title":"New Engl J Med"},{"issue":"2","key":"2289_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Pitt B et al (2021) Sotagliflozin in patients with diabetes and chronic kidney disease. New Engl J Med 384(2):129\u2013139. https:\/\/doi.org\/10.1056\/NEJMoa2030186","journal-title":"New Engl J Med"},{"issue":"10","key":"2289_CR19","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","volume":"385","author":"HC Gerstein","year":"2021","unstructured":"Gerstein HC, Sattar N, Rosenstock J et al (2021) Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. New Engl J Med 385(10):896\u2013907. https:\/\/doi.org\/10.1056\/NEJMoa2108269","journal-title":"New Engl J Med"},{"issue":"3","key":"2289_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14780","volume":"39","author":"R Sim","year":"2022","unstructured":"Sim R, Chong CW, Loganadan NK et al (2022) Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Diabetic Med 39(3):e14780. https:\/\/doi.org\/10.1111\/dme.14780","journal-title":"Diabetic Med"},{"key":"2289_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1043789","author":"L Liu","year":"2022","unstructured":"Liu L, Chen J, Wang L, Chen C, Chen L (2022) Association between different glp-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on fda adverse event reporting system database. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2022.1043789","journal-title":"Front Endocrinol"},{"issue":"3","key":"2289_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2022.102427","volume":"16","author":"R Shetty","year":"2022","unstructured":"Shetty R, Basheer FT, Poojari PG, Thunga G, Chandran VP, Acharya LD (2022) Adverse drug reactions of glp-1 agonists: a systematic review of case reports. Diabetes Metab Synd 16(3):102427. https:\/\/doi.org\/10.1016\/j.dsx.2022.102427","journal-title":"Diabetes Metab Synd"},{"issue":"5","key":"2289_CR23","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","volume":"182","author":"L He","year":"2022","unstructured":"He L, Wang J, Ping F et al (2022) Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. Jama Intern Med 182(5):513\u2013519. https:\/\/doi.org\/10.1001\/jamainternmed.2022.0338","journal-title":"Jama Intern Med"},{"issue":"34","key":"2289_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000030072","volume":"101","author":"YW Wang","year":"2022","unstructured":"Wang YW, Lin JH, Yang CS (2022) Meta-analysis of the association between new hypoglycemic agents and digestive diseases. Medicine 101(34):e30072. https:\/\/doi.org\/10.1097\/MD.0000000000030072","journal-title":"Medicine"},{"issue":"4","key":"2289_CR25","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1080\/17512433.2020.1736041","volume":"13","author":"AK Singh","year":"2020","unstructured":"Singh AK, Gangopadhyay KK, Singh R (2020) Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials. Expert Rev Clin Phar 13(4):461\u2013468. https:\/\/doi.org\/10.1080\/17512433.2020.1736041","journal-title":"Expert Rev Clin Phar"},{"issue":"4","key":"2289_CR26","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/dom.13924","volume":"22","author":"EAM Abd","year":"2020","unstructured":"Abd EAM, Cahyadi O, Meier JJ, Schmidt WE, Nauck MA (2020) Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Diabetes Obes Metab 22(4):699\u2013704. https:\/\/doi.org\/10.1111\/dom.13924","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"2289_CR27","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.eprac.2021.12.007","volume":"28","author":"X Zhang","year":"2022","unstructured":"Zhang X, Wang M, Wang X et al (2022) Comparison of new glucose-lowering drugs on the risk of pancreatitis in type 2 diabetes: a network meta-analysis. Endocr Pract 28(3):333\u2013341. https:\/\/doi.org\/10.1016\/j.eprac.2021.12.007","journal-title":"Endocr Pract"},{"key":"2289_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1238399","author":"CX Li","year":"2023","unstructured":"Li CX, Liu LY, Zhang CX et al (2023) Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2023.1238399","journal-title":"Front Endocrinol"},{"key":"2289_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-023-06908-2","author":"X Wang","year":"2023","unstructured":"Wang X, Zhang F, Zhang Y et al (2023) Effect of sglt2 inhibitors on fractures, bmd, and bone metabolism markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Osteoporosis Int. https:\/\/doi.org\/10.1007\/s00198-023-06908-2","journal-title":"Osteoporosis Int"},{"issue":"10","key":"2289_CR30","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00198-019-04968-x","volume":"30","author":"K Hidayat","year":"2019","unstructured":"Hidayat K, Du X, Shi BM (2019) Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies. Osteoporosis Int 30(10):1923\u20131940. https:\/\/doi.org\/10.1007\/s00198-019-04968-x","journal-title":"Osteoporosis Int"},{"issue":"2","key":"2289_CR31","doi-asserted-by":"publisher","first-page":"1476853704","DOI":"10.1177\/14791641211011016","volume":"18","author":"M Qiu","year":"2021","unstructured":"Qiu M, Ding LL, Zhang M, Zhou HR (2021) Safety of four sglt2 inhibitors in three chronic diseases: a meta-analysis of large randomized trials of sglt2 inhibitors. Diabetes Vasc Dis Re 18(2):1476853704. https:\/\/doi.org\/10.1177\/14791641211011016","journal-title":"Diabetes Vasc Dis Re"},{"key":"2289_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.1010693","author":"A Mascolo","year":"2022","unstructured":"Mascolo A, Di Napoli R, Balzano N et al (2022) Safety profile of sodium glucose co-transporter 2 (sglt2) inhibitors: a brief summary. Front Cardiovasc Med. https:\/\/doi.org\/10.3389\/fcvm.2022.1010693","journal-title":"Front Cardiovasc Med"},{"key":"2289_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.735824","author":"YS Zhang","year":"2021","unstructured":"Zhang YS, Zheng YD, Yuan Y, Chen SC, Xie BC (2021) Effects of anti-diabetic drugs on fracture risk: a systematic review and network meta-analysis. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2021.735824","journal-title":"Front Endocrinol"},{"key":"2289_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13611","author":"D Fitchett","year":"2019","unstructured":"Fitchett D (2019) A safety update on sodium glucose co-transporter 2 inhibitors. Diabetes Obes Metab. https:\/\/doi.org\/10.1111\/dom.13611","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"2289_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. Plos Med 6(7):e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"Plos Med"},{"key":"2289_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC et al (2011) The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ-Brit Med J. https:\/\/doi.org\/10.1136\/bmj.d5928","journal-title":"BMJ-Brit Med J"},{"issue":"19","key":"2289_CR37","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New Engl J Med 375(19):1834\u20131844. https:\/\/doi.org\/10.1056\/NEJMoa1607141","journal-title":"New Engl J Med"},{"issue":"10193","key":"2289_CR38","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (rewind): a double-blind, randomised placebo-controlled trial. Lancet 394(10193):121\u2013130. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3","journal-title":"Lancet"},{"issue":"13","key":"2289_CR39","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ et al (2017) Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. New Engl J Med 377(13):1228\u20131239. https:\/\/doi.org\/10.1056\/NEJMoa1612917","journal-title":"New Engl J Med"},{"issue":"10077","key":"2289_CR40","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","volume":"389","author":"CW le Roux","year":"2017","unstructured":"le Roux CW, Astrup A, Fujioka K et al (2017) 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 389(10077):1399\u20131409. https:\/\/doi.org\/10.1016\/S0140-6736(17)30069-7","journal-title":"Lancet"},{"issue":"9","key":"2289_CR41","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M et al (2019) Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New Engl J Med 381(9):841\u2013851. https:\/\/doi.org\/10.1056\/NEJMoa1901118","journal-title":"New Engl J Med"},{"issue":"4","key":"2289_CR42","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. New Engl J Med 375(4):311\u2013322. https:\/\/doi.org\/10.1056\/NEJMoa1603827","journal-title":"New Engl J Med"},{"issue":"10313","key":"2289_CR43","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","volume":"398","author":"PS Del","year":"2021","unstructured":"Del PS, Kahn SE, Pavo I et al (2021) Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (surpass-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 398(10313):1811\u20131824. https:\/\/doi.org\/10.1016\/S0140-6736(21)02188-7","journal-title":"Lancet"},{"issue":"15","key":"2289_CR44","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1001\/jama.2019.2942","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Allison D, Birkenfeld AL et al (2019) Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the pioneer 3 randomized clinical trial. Jama-J Am Med Assoc 321(15):1466\u20131480. https:\/\/doi.org\/10.1001\/jama.2019.2942","journal-title":"Jama-J Am Med Assoc"},{"issue":"5","key":"2289_CR45","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"VR Aroda","year":"2017","unstructured":"Aroda VR, Bain SC, Cariou B et al (2017) Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (sustain 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endo 5(5):355\u2013366. https:\/\/doi.org\/10.1016\/S2213-8587(17)30085-2","journal-title":"Lancet Diabetes Endo"},{"issue":"5","key":"2289_CR46","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","volume":"5","author":"B Ahr\u00e9n","year":"2017","unstructured":"Ahr\u00e9n B, Masmiquel L, Kumar H et al (2017) Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (sustain 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endo 5(5):341\u2013354. https:\/\/doi.org\/10.1016\/S2213-8587(17)30092-X","journal-title":"Lancet Diabetes Endo"},{"issue":"23","key":"2289_CR47","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R et al (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. New Engl J Med 373(23):2247\u20132257. https:\/\/doi.org\/10.1056\/NEJMoa1509225","journal-title":"New Engl J Med"},{"issue":"10157","key":"2289_CR48","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S et al (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392(10157):1519\u20131529. https:\/\/doi.org\/10.1016\/S0140-6736(18)32261-X","journal-title":"Lancet"},{"issue":"21","key":"2289_CR49","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"J McMurray","year":"2019","unstructured":"McMurray J, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. New Engl J Med 381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303","journal-title":"New Engl J Med"},{"issue":"15","key":"2289_CR50","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. New Engl J Med 383(15):1413\u20131424. https:\/\/doi.org\/10.1056\/NEJMoa2022190","journal-title":"New Engl J Med"},{"issue":"15","key":"2289_CR51","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"H Heerspink","year":"2020","unstructured":"Heerspink H, Stef\u00e1nsson BV, Correa-Rotter R et al (2020) Dapagliflozin in patients with chronic kidney disease. New Engl J Med 383(15):1436\u20131446. https:\/\/doi.org\/10.1056\/NEJMoa2024816","journal-title":"New Engl J Med"},{"issue":"7","key":"2289_CR52","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. New Engl J Med 377(7):644\u2013657. https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"New Engl J Med"},{"issue":"4","key":"2289_CR53","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New Engl J Med 380(4):347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"New Engl J Med"},{"key":"2289_CR54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004967","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S et al (2020) Cardiovascular outcomes with ertugliflozin in type 2 diabetes. New Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2004967","journal-title":"New Engl J Med"},{"issue":"24","key":"2289_CR55","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. New Engl J Med 380(24):2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744","journal-title":"New Engl J Med"},{"issue":"22","key":"2289_CR56","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New Engl J Med 373(22):2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"New Engl J Med"},{"key":"2289_CR57","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15251","author":"M Sohn","year":"2023","unstructured":"Sohn M, Frias JP, Lim S (2023) Cardiovascular efficacy and safety of antidiabetic agents: a network meta-analysis of randomized controlled trials. Diabetes Obes Metab. https:\/\/doi.org\/10.1111\/dom.15251","journal-title":"Diabetes Obes Metab"},{"key":"2289_CR58","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-031620-095920","author":"V Vallon","year":"2021","unstructured":"Vallon V, Verma S (2021) Effects of sglt2 inhibitors on kidney and cardiovascular function. Annu Rev Physiol. https:\/\/doi.org\/10.1146\/annurev-physiol-031620-095920","journal-title":"Annu Rev Physiol"},{"key":"2289_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-023-01417-5","author":"N Oshima","year":"2023","unstructured":"Oshima N, Onimaru H, Yamashiro A et al (2023) Sglt2 and sglt1 inhibitors suppress the activities of the rvlm neurons in newborn wistar rats. Hypertens Res. https:\/\/doi.org\/10.1038\/s41440-023-01417-5","journal-title":"Hypertens Res"},{"issue":"7","key":"2289_CR60","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1042\/CS20210094","volume":"135","author":"KN Miyata","year":"2021","unstructured":"Miyata KN, Lo CS, Zhao S et al (2021) Angiotensin ii up-regulates sodium-glucose co-transporter 2 expression and sglt2 inhibitor attenuates ang ii-induced hypertensive renal injury in mice. Clin Sci 135(7):943\u2013961. https:\/\/doi.org\/10.1042\/CS20210094","journal-title":"Clin Sci"},{"issue":"12","key":"2289_CR61","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1007\/s00198-018-4649-8","volume":"29","author":"YS Zhang","year":"2018","unstructured":"Zhang YS, Weng WY, Xie BC et al (2018) Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials. Osteoporosis Int 29(12):2639\u20132644. https:\/\/doi.org\/10.1007\/s00198-018-4649-8","journal-title":"Osteoporosis Int"},{"issue":"7","key":"2289_CR62","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3168","volume":"35","author":"L Cheng","year":"2019","unstructured":"Cheng L, Hu Y, Li YY et al (2019) Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes-Metab Res 35(7):e3168. https:\/\/doi.org\/10.1002\/dmrr.3168","journal-title":"Diabetes-Metab Res"},{"issue":"6","key":"2289_CR63","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1507\/endocrj.EJ21-0129","volume":"68","author":"DG Yin","year":"2021","unstructured":"Yin DG, Ding LL, Zhou HR, Qiu M, Duan XY (2021) Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the sustain and pioneer trials. Endocr J 68(6):739\u2013742. https:\/\/doi.org\/10.1507\/endocrj.EJ21-0129","journal-title":"Endocr J"},{"key":"2289_CR64","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99123","author":"JE Blau","year":"2018","unstructured":"Blau JE, Bauman V, Conway EM et al (2018) Canagliflozin triggers the fgf23\/1,25-dihydroxyvitamin d\/pth axis in healthy volunteers in a randomized crossover study. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.99123","journal-title":"JCI Insight"},{"issue":"2","key":"2289_CR65","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3100","volume":"35","author":"E Kalaitzoglou","year":"2019","unstructured":"Kalaitzoglou E, Fowlkes JL, Popescu I, Thrailkill KM (2019) Diabetes pharmacotherapy and effects on the musculoskeletal system. Diabetes-Metab Res 35(2):e3100. https:\/\/doi.org\/10.1002\/dmrr.3100","journal-title":"Diabetes-Metab Res"},{"issue":"6","key":"2289_CR66","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/j.pharep.2017.05.008","volume":"69","author":"M Adil","year":"2017","unstructured":"Adil M, Khan RA, Kalam A et al (2017) Effect of anti-diabetic drugs on bone metabolism: evidence from preclinical and clinical studies. Pharmacol Rep 69(6):1328\u20131340. https:\/\/doi.org\/10.1016\/j.pharep.2017.05.008","journal-title":"Pharmacol Rep"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-024-02289-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-024-02289-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-024-02289-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T09:04:44Z","timestamp":1725613484000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00592-024-02289-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,7]]},"references-count":66,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["2289"],"URL":"https:\/\/doi.org\/10.1007\/s00592-024-02289-y","relation":{},"ISSN":["1432-5233"],"issn-type":[{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,7]]},"assertion":[{"value":"4 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"He authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Ethical approval was not required because this article does not contain any studies with human subjects or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was not required because this article does not contain any studies with human subjects performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}